There is a growing impetus to bring an entrepreneurial ethic and greater manageability to the research mission at both university and corporate labs so as to reduce the 12-15 year cycle time and the over $500 million cost to bring new drugs to the market.

Of particular value will be technology that allows researchers to validate drug targets and increase throughput coefficients. In turn, individuals and firms with the expertise and experience to understand and charter the regulatory process have become significant assets in the global biotechnology-pharmaceutical merger of economic and scientific models.

Kansas City is well positioned with such expertise and market presence throughout the value chain from basic and applied research to clinical testing and monitoring to drug delivery and management.